Bioequivalence of fexofenadine tablet formulations assessed in healthy iranian volunteers

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 7, 2009, Pages 345-349

  Valizadeh, Hadi ^a,b   Barghi, Leila ^c   Jalilian, Hadi ^a   Islambulchilar, Ziba ^d   Zakeri Milani, Parvin ^a,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antihistaminic drugs; CAS 153439 40 8; Fexofenadine, bioavailability, bioequivalency, HPLC, pharmacokinetics

Indexed keywords

FEXOFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IRAN; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; TABLET FORMULATION;

EID: 69249098197     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296406     Document Type: Article

References (12)

1. Isleyen EAÖ, Özden T, Toptan S. Quantitative Determination of Fexofenadine in Human Plasma by HPLC-MS. Chromatographia. 2007;66:109-113 (Pubitemid 47437232)
2. Hofmann U, Seiler M, Drescher S, Fromm MF. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;766(2):227-233 (Pubitemid 34142354)
3. Ujie K, Oda M, Kobayashi M, Saitoh H. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats. Int J Pharm. 2008; 361:7-11.
4. Sweetman SC. Martindale: The Complete Drug Reference. London: The Pharmaceutical Press; 2007.
5. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D. 2007;8(5):301-314 (Pubitemid 47403125)
6. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J PharmSci. 2006;95(9):1984-1993 (Pubitemid 44433029)
7. Perloff MDP, von Moltke LLMD, Greenblatt DJMD. Fexofenadine Transport in Caco-2 Cells: Inhibition with Verapamil and Ritonavir. J Clin Pharmacol. 2002;42(11):1269-1274
8. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality. 2007;19(3):223-227 (Pubitemid 46311056)
9. Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet. 2002;41(4): 311-318 (Pubitemid 34533758)
10. Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008;58(2):97-100. (Pubitemid 351346430)
11. Surapaneni S, khalil SKW. A sensitive HPLC method for the determination of terfenadine and its metabolite in human plasma. J Liquid Chromatogr. 1994;17(11):2419-2428 (Pubitemid 24234627)
12. Coutant JE, Westmark PA, Nardella PA, Marc Walter S, Okerholm RA. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr . 1991;570(1):139-148